Author

Federico Argüelles-Arias 1

1 Hospital Universitario Virgen Macarena,Sevilla,Spain

Are cut-off ranges of Infliximab serum levels in Crohn´s disease always the same in clinical practice?

Teresa Valdes-Delgado, Maria Fernanda Guerra Veloz, Federico Argüelles-Arias, Belen Maldonado Pérez, Luisa Castro Laria, Ángel Caunedo-Álvarez

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Maria Chaparro, Sara Sulleiro, Iria Baston-Rey, Ivan Garcia Tercero, Federico Argüelles-Arias, Eduardo Leo, Cristina Rodriguez, Beatriz Sicilia, Patricia Ramírez de la Piscina, Sabino Riestra, Mercedes Cabello, Pilar Corsino, Maria Jose Garcia, Mariana Fé García-Sepulcre, José María Huguet, Pilar Martínez-Montiel, Fernando

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

Raúl Olmedo-Martín, Laura Lorenzo-González, Marta Lázaro-Sáez, Federico Argüelles-Arias, Juan Maria Vázquez Morón, Manuel López-Vico, Alvaro Hernández Martínez, Maria Mar Martin Rodriguez

INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SOUTHERN SPAIN (ANDALUSIA)

Beatriz Gros Alcalde, Jose Manuel Benitez, Juan Maria Vázquez Morón, Pilar Soto Escribano, Raúl Vicente Olmedo Martín, Federico Argüelles-Arias, Raquel Camargo Camero, Paula Fernandez Alvarez, María del Mar Martín Rodríguez, Claudio Trigo Salado, Ana María Trapero Martinez, Sandra Marín Pedrosa, Eva Iglesias, Marta Lázaro Sáez

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Yamile Zabana Abdo, Maria Isabel Vera Mendoza, Iván Guerra, Olga Benítez, Iago Rodríguez-Lago, Francisco Mesonero Gismero, Ignacio Marín-Jiménez, Javier Gisbert, María Dolores Martín-Arranz, Angel Ponferrada Diaz, Pilar Martínez-Montiel, Maia Boscá-Watts, Teresa Pérez-Martínez, Cristina Rodríguez Gutiérrez, Santiago Martínez-

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Maria Chaparro, Sara Sulleiro, Iria Baston-Rey, Ivan Garcia Tercero, Federico Argüelles-Arias, Eduardo Leo, Cristina Rodriguez, Beatriz Sicilia, Patricia Ramírez de la Piscina, Sabino Riestra, Mercedes Cabello, Santiago García-López, Maria Jose Garcia, Mariana Fé García-Sepulcre, José María Huguet, Pilar Martínez-Montiel, F

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María José Casanova, Maria Chaparro, Oscar Nantes Castillejo, Jose Manuel Benitez, Maria Rojas-Feria, Jesus Castro Poceiro, J. M. Huguet-Malavés, Albert Martin-Cardona, M Aicart, Joan Tosca, MM Martín-Rodríguez, Carlos Gonzalez Muñoza, Miriam Mañosa, Eduardo Leo Carnerero, Luis Javier Lamuela-Calvo, Isabel Pérez-Martínez, L

Long-term follow-up of switching from original infliximab to infliximab biosimilar. Real world data

Maria Belvis Jiménez, Maria Fernanda Guerra Veloz, Belen Maldonado Pérez, Teresa Valdes-Delgado, Luisa Castro Laria, Raul Perea, Javier Calleja, Vicente Merino, Antonio Benítez Roldán, Ángel Caunedo Álvarez, Federico Argüelles-Arias

Real life experience of first line anti-TNF in Crohn´s disease patients in Spain: do we have data to choose between infliximab and adalimumab?

Ignacio Marín-Jiménez, Guillermo Bastida, Ana Fores, Federico Argüelles-Arias, Ignacio Tagarro, Alonso Fernandez, Carmen Montoto Otero, Mariam Aguas, Rocio Ferreiro Iglesias, Olga Merino, Javier Santos Fernandez, Xavier Cortés, Francisco Mesonero Gismero, Manuel Barreiro de Acosta

SELF-CONFIDENCE, EMOTIONAL HEALTH AND HEALTH RESOURCES CONSUMPTION AMONG SPANISH PATIENTS WITH ULCERATIVE COLITIS. UC-LIFE SURVEY

Daniel Carpio Lopez, Federico Argüelles-Arias, Xavier Calvet Calvo, Luis Cea, Berta Juliá De Páramo, Cristina Romero, Antonio López San Román

Item 1 - 10 / 15
1
2